Paracetamol 120Mg/5mL Oral Suspension ( DrugBank: Paracetamol )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 3 | Spinal muscular atrophy | 1 |
3. Spinal muscular atrophy
Clinical trials : 237 / Drugs : 123 - (DrugBank : 29) / Drug target genes : 51 - Drug target pathways : 75
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03648658 (ClinicalTrials.gov) | February 18, 2019 | 8/8/2018 | Paracetamol Study in Patients With Low Muscle Mass | Pharmacokinetics and Safety of Treatment With Paracetamol in Children and Adults With Spinal Muscular Atrophy and Cerebral Palsy | SMA II;Cerebral Palsy | Drug: Paracetamol 120Mg/5mL Oral Suspension | Mette Cathrine Oerngreen | Elsass Foundation | Recruiting | 6 Years | 45 Years | All | 48 | Phase 4 | Denmark |